235 related articles for article (PubMed ID: 35735135)
1. Hyaluronic Acid-PEG-Based Diels-Alder
Ilochonwu BC; Mihajlovic M; Maas-Bakker RF; Rousou C; Tang M; Chen M; Hennink WE; Vermonden T
Biomacromolecules; 2022 Jul; 23(7):2914-2929. PubMed ID: 35735135
[TBL] [Abstract][Full Text] [Related]
2. Thermo-responsive Diels-Alder stabilized hydrogels for ocular drug delivery of a corticosteroid and an anti-VEGF fab fragment.
Ilochonwu BC; van der Lugt SA; Annala A; Di Marco G; Sampon T; Siepmann J; Siepmann F; Hennink WE; Vermonden T
J Control Release; 2023 Sep; 361():334-349. PubMed ID: 37532147
[TBL] [Abstract][Full Text] [Related]
3. In situ antibody-loaded hydrogel for intravitreal delivery.
Awwad S; Abubakre A; Angkawinitwong U; Khaw PT; Brocchini S
Eur J Pharm Sci; 2019 Sep; 137():104993. PubMed ID: 31302214
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal injectable hydrogel rods with long-acting bevacizumab delivery to the retina.
Lee S; Hong HK; Song JS; Jeong SI; Chung JY; Woo SJ; Park KD
Acta Biomater; 2023 Nov; 171():273-288. PubMed ID: 37739248
[TBL] [Abstract][Full Text] [Related]
5. An injectable thermosensitive polymeric hydrogel for sustained release of Avastin® to treat posterior segment disease.
Xie B; Jin L; Luo Z; Yu J; Shi S; Zhang Z; Shen M; Chen H; Li X; Song Z
Int J Pharm; 2015 Jul; 490(1-2):375-83. PubMed ID: 26027491
[TBL] [Abstract][Full Text] [Related]
6. Diels-Alder hydrogels with enhanced stability: First step toward controlled release of bevacizumab.
Kirchhof S; Gregoritza M; Messmann V; Hammer N; Goepferich AM; Brandl FP
Eur J Pharm Biopharm; 2015 Oct; 96():217-25. PubMed ID: 26253504
[TBL] [Abstract][Full Text] [Related]
7. Diels-Alder mediated controlled release from a poly(ethylene glycol) based hydrogel.
Koehler KC; Anseth KS; Bowman CN
Biomacromolecules; 2013 Feb; 14(2):538-47. PubMed ID: 23311608
[TBL] [Abstract][Full Text] [Related]
8. Biodegradable hyaluronic acid hydrogels to control release of dexamethasone through aqueous Diels-Alder chemistry for adipose tissue engineering.
Fan M; Ma Y; Zhang Z; Mao J; Tan H; Hu X
Mater Sci Eng C Mater Biol Appl; 2015 Nov; 56():311-7. PubMed ID: 26249595
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the sustained release ability of bevacizumab-loaded tetra-PEG gel.
Murakami T; Hoshi S; Okamoto F; Sakai T; Katashima T; Naito M; Oshika T
Exp Eye Res; 2022 Oct; 223():109206. PubMed ID: 35921961
[TBL] [Abstract][Full Text] [Related]
10. Controlled release of MSC-derived small extracellular vesicles by an injectable Diels-Alder crosslinked hyaluronic acid/PEG hydrogel for osteoarthritis improvement.
Yang Y; Zhu Z; Gao R; Yuan J; Zhang J; Li H; Xie Z; Wang Y
Acta Biomater; 2021 Jul; 128():163-174. PubMed ID: 33862283
[TBL] [Abstract][Full Text] [Related]
11. In situ covalently cross-linked PEG hydrogel for ocular drug delivery applications.
Yu J; Xu X; Yao F; Luo Z; Jin L; Xie B; Shi S; Ma H; Li X; Chen H
Int J Pharm; 2014 Aug; 470(1-2):151-7. PubMed ID: 24768405
[TBL] [Abstract][Full Text] [Related]
12. Controlled Antibody Release from Degradable Thermoresponsive Hydrogels Cross-Linked by Diels-Alder Chemistry.
Gregoritza M; Messmann V; Abstiens K; Brandl FP; Goepferich AM
Biomacromolecules; 2017 Aug; 18(8):2410-2418. PubMed ID: 28639788
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronic acid-based nanocomposite hydrogels for ocular drug delivery applications.
Widjaja LK; Bora M; Chan PN; Lipik V; Wong TT; Venkatraman SS
J Biomed Mater Res A; 2014 Sep; 102(9):3056-65. PubMed ID: 24124098
[TBL] [Abstract][Full Text] [Related]
14. Six-month sustained delivery of anti-VEGF from in-situ forming hydrogel in the suprachoroidal space.
Jung JH; Kim SS; Chung H; Hejri A; Prausnitz MR
J Control Release; 2022 Dec; 352():472-484. PubMed ID: 36309098
[TBL] [Abstract][Full Text] [Related]
15. Diels-Alder Hydrogels for Controlled Antibody Release: Correlation between Mesh Size and Release Rate.
Kirchhof S; Abrami M; Messmann V; Hammer N; Goepferich AM; Grassi M; Brandl FP
Mol Pharm; 2015 Sep; 12(9):3358-68. PubMed ID: 26266700
[TBL] [Abstract][Full Text] [Related]
16. Oligonucleotide-functionalized hydrogels for sustained release of small molecule (aptamer) therapeutics.
Agrawal NK; Allen P; Song YH; Wachs RA; Du Y; Ellington AD; Schmidt CE
Acta Biomater; 2020 Jan; 102():315-325. PubMed ID: 31760222
[TBL] [Abstract][Full Text] [Related]
17. Bio-Orthogonal Cross-Linking Chemistry Enables In Situ Protein Encapsulation and Provides Sustained Release from Hyaluronic Acid Based Hydrogels.
Famili A; Rajagopal K
Mol Pharm; 2017 Jun; 14(6):1961-1968. PubMed ID: 28463007
[TBL] [Abstract][Full Text] [Related]
18. Injectable Diels-Alder cycloaddition hydrogels with tuneable gelation, stiffness and degradation for the sustained release of T-lymphocytes.
Yan J; Gundsambuu B; Krasowska M; Platts K; Facal Marina P; Gerber C; Barry SC; Blencowe A
J Mater Chem B; 2022 May; 10(17):3329-3343. PubMed ID: 35380575
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, physicochemical properties and ocular pharmacokinetics of thermosensitive in situ hydrogels for ganciclovir in cytomegalovirus retinitis treatment.
Wang Q; Sun C; Xu B; Tu J; Shen Y
Drug Deliv; 2018 Nov; 25(1):59-69. PubMed ID: 29228826
[TBL] [Abstract][Full Text] [Related]
20. Prevention of corneal neovascularization by subconjunctival injection of avastin® loaded thermosensitive hydrogels in rabbit model.
Xu X; Yu J; Shi H; Zhang J; Li X
Int J Pharm; 2018 Dec; 552(1-2):164-170. PubMed ID: 30217769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
